United Therapeutics Co. (NASDAQ:UTHR) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of United Therapeutics Co. (NASDAQ:UTHR) have been given an average rating of “Moderate Buy” by the fifteen research firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and twelve have given a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $370.86.

UTHR has been the topic of a number of recent research reports. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Monday, December 30th. LADENBURG THALM/SH SH increased their target price on United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. The Goldman Sachs Group boosted their price objective on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research note on Friday, November 1st. Jefferies Financial Group raised their target price on United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a research note on Monday, September 23rd. Finally, Argus upped their price target on United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday, October 31st.

Insider Transactions at United Therapeutics

In other news, CFO James Edgemond sold 7,794 shares of the stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $355.54, for a total transaction of $2,771,078.76. Following the transaction, the chief financial officer now directly owns 5,344 shares in the company, valued at approximately $1,900,005.76. This represents a 59.32 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Nilda Mesa sold 255 shares of the firm’s stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $355.77, for a total value of $90,721.35. Following the transaction, the director now directly owns 5,528 shares in the company, valued at approximately $1,966,696.56. This represents a 4.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 150,216 shares of company stock valued at $56,269,811 in the last quarter. Insiders own 11.90% of the company’s stock.

Institutional Investors Weigh In On United Therapeutics

A number of institutional investors have recently made changes to their positions in the business. ClariVest Asset Management LLC lifted its stake in United Therapeutics by 120.0% in the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 42 shares during the last quarter. USA Financial Formulas bought a new stake in shares of United Therapeutics in the 3rd quarter valued at about $33,000. Brooklyn Investment Group purchased a new stake in United Therapeutics during the 3rd quarter valued at about $33,000. Capital Performance Advisors LLP bought a new position in United Therapeutics during the 3rd quarter worth approximately $82,000. Finally, Values First Advisors Inc. purchased a new position in United Therapeutics in the 3rd quarter worth approximately $90,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $356.33 on Monday. United Therapeutics has a 1 year low of $208.62 and a 1 year high of $417.82. The business has a fifty day simple moving average of $370.42 and a two-hundred day simple moving average of $350.39. The company has a market capitalization of $15.91 billion, a P/E ratio of 15.65, a P/E/G ratio of 1.05 and a beta of 0.55.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. The business had revenue of $748.90 million for the quarter, compared to analysts’ expectations of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm’s quarterly revenue was up 22.9% compared to the same quarter last year. During the same period in the previous year, the business posted $5.38 EPS. As a group, analysts anticipate that United Therapeutics will post 25.22 earnings per share for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.